Articles
Just over one year into the second Trump administration, the US healthcare and life science market is navigating a steady stream of series of unprecedented policy shifts. Long defined by patients in the US having more innovative medicines available to them than anywhere else on earth, but the market’s long-criticized high prices and fragmented delivery…
Successive American governments have grappled with the need to contain spiraling healthcare costs while sustaining the USA’s well-earned reputation as the number one launch market for breakthrough medical innovations. “The most difficult question of our time in our sector relates to how to fund access to advanced therapies,” explains Marwan Fathallah, president and CEO of…
For many years, the US has been considered the unequivocal champion in the global war against cancer. Not only does the country presently account for approximately 57 percent of worldwide cancer research funding, but American per capita investment in oncology research averages as much as seven times higher than that of Western Europe. Meanwhile, the…
America – once the undisputed global leader in medicine manufacturing – is today more reliant on pharma imports than at any time in its history. This dependence has steadily increased since the turn of the millennium, as large portions of the manufacturing chain were outsourced to low-cost suppliers in India and China, and led to…
The US rare and ultra-rare disease market constitutes a cornerstone of the worldwide pharmaceutical industry, representing a full 52.3 percent of the total global market share in revenue for that therapeutic area. America also plays an outsized role in driving international medical innovation in that field – housing nearly 60 percent of all life science…
Although best-known for its dermo-cosmetics, pharmaceuticals account for 50 percent of Pierre Fabre’s revenues, and the company has been engaged in cancer care for almost half a century. Now, it is ramping up its pharmaceutical presence in the US with the creation of a dedicated pharma unit, the inauguration of a new US headquarters, and…
When Nasha Fitter’s daughter, Amara, was diagnosed with the ultra-rare FOXG1 syndrome at just seven months old, the prognosis was stark: no speech, no independent movement, severe intellectual disability, and lifelong epilepsy. For many families, such a diagnosis marks the beginning of a long wait – for care, for answers, for science to catch up.…
